MacroGenics, Inc. (MGNX)

Oncology Corporate Profile

Stock Performance

17.9900
0.0000

HQ Location

9640 Medical Center Drive
Rockville, MD 20850

Company Description

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies.  Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases.  Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe.

Website: http://www.macrogenics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
margetuximabanti-HER2 monoclonal antibodyBreast cancerIIIGreen Cross
margetuximabanti-HER2 monoclonal antibodyBreast cancerIIGreen Cross
margetuximab (+pembrolizumab)anti-HER2 monoclonal antibodyGastric cancerIIGreen Cross
MGD006dual-affinity re-targeting (DART) moleculeAcute Myelogenous Leukemia (AML)IServier
MGD007dual-affinity re-targeting (DART) moleculeColorectal cancerIServier
MGD011bispecific dual-affinity re-targeting (DART) moleculeLymphomaIJanssen
MGD006dual-affinity re-targeting (DART) moleculeMyelodysplastic Syndrome (MDS)IServier
enoblituzumab / MGA271monoclonal antibodyVarious cancer typesI
MGD009dual-affinity re-targeting (DART) moleculeVarious cancer typesI

View additional information on product candidates here »

Source


http://www.macrogenics.com/

Recent News Headlines

MACROGENICS INC Financials

3/7/2017 06:00 pm

MacroGenics Provides Update on Corporate Progress and 2016 Financial Results

2/28/2017 09:00 pm

[GlobeNewswire] - ROCKVILLE, Md., Feb. 28, 2017-- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

MacroGenics to Participate in Two Upcoming Investor Conferences

2/27/2017 10:03 pm

[GlobeNewswire] - Rockville, MD, Feb. 27, 2017---- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment ...

MacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call

2/16/2017 09:03 pm

[GlobeNewswire] - ROCKVILLE, MD, Feb. 16, 2017-- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

MacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference

2/9/2017 11:00 pm

[GlobeNewswire] - ROCKVILLE, MD, Feb. 09, 2017-- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

MacroGenics Announces Appointments to Board of Directors

1/25/2017 09:03 pm

[GlobeNewswire] - Rockville, MD, Jan. 25, 2017-- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA

1/5/2017 09:05 pm

[at noodls] - ROCKVILLE, MD, Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based ...

MacroGenics’ MGD006 Granted Orphan Drug Status for AML by FDA

1/5/2017 09:03 pm

[GlobeNewswire] - ROCKVILLE, MD, Jan. 05, 2017--. MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

MacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/5/2017 12:03 pm

[GlobeNewswire] - ROCKVILLE, MD, Jan. 05, 2017--. MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

MacroGenics Highlights Progress at 2016 R&D Day

12/13/2016 05:03 pm

[GlobeNewswire] - Advancement of HER2 franchise led by margetuximab Expansion and progression of B7-H3 franchise Introduction of PD-1 directed immuno-oncology franchise Clinical updates on multiple DART ® studies underscore ...

MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC

12/12/2016 09:03 pm

[GlobeNewswire] - ROCKVILLE, Md. and NIJMEGEN, the Netherlands, Dec. 12, 2016--. MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics ...